Bulevirtide

Summary

Bulevirtide (brand name Hepcludex) is the first approved entry inhibitor for chronic hepatitis D virus (HDV) infection in adults with compensated liver disease. It received conditional marketing authorization from the European Medicines Agency (EMA) in 2020 and full approval in 2024. It is administered as a once-daily subcutaneous injection.

Mechanism of Action

Bulevirtide is a synthetic lipopeptide derived from the preS1 domain of hepatitis B virus (HBV) surface antigen. It competitively blocks the sodium taurocholate cotransporting polypeptide (NTCP/SLC10A1), the hepatic receptor used by both HBV and hepatitis D virus (HDV) for cell entry, thereby preventing viral uptake into hepatocytes.

Routes of Administration

Goals & Uses

• ALT normalization in chronic HDVHepatic Inflammation ReductionHigh
• Suppression of HDV RNAAntiviral EfficacyHigh
• Combination therapy with pegylated interferon-alphaCombination Antiviral StrategyModerate
• Prevention of HBV/HDV co-entryAntiviral MechanismHigh
• Reduction of liver fibrosis progressionHepatoprotectionModerate

Contraindications

• Concurrent use of NTCP-inhibiting drugs (e.g., cyclosporine, certain statins)Drug InteractionModerate
• Hypersensitivity to bulevirtide or excipientsAllergy/immunologicHigh
• Decompensated liver diseaseHepatic ImpairmentHigh

Adverse Effects

• Pruritus (systemic)DermatologicCommon
• HBV DNA or surface antigen increase upon discontinuationVirologic ReboundUncommon
• Injection site reactionsLocalCommon
• HeadacheNeurologicUncommonPain in the head or upper neck
• FatigueGeneralUncommonLow energy or tiredness
• Elevated bile acid levels (hypercholanemia)MetabolicCommon

Drug Interactions

• RifampicinModerate
• CyclosporineHigh
• Tenofovir alafenamide / nucleos(t)ide analogues for HBVLow
• Statins (NTCP substrates, e.g., rosuvastatin)Moderate

Population Constraints

• PregnancyReproductive SafetyRelative
• Severe renal impairmentOrgan ImpairmentRelative
• Pediatric patients (<18 years)AgeAbsolute
• Decompensated cirrhosis (Child-Pugh B/C)Hepatic ImpairmentAbsolute
• BreastfeedingReproductiveRelative

Regulatory Status

• European UnionApprovedApproved: Chronic hepatitis D virus (HDV) infection in adults with compensated liver diseaseConditional marketing authorization granted July 2020 by EMA; converted to full approval 2024. Orphan designation.
• United StatesInvestigationalNot FDA-approved as of 2024. Under investigation in clinical trials. Breakthrough therapy designation not confirmed.
• United KingdomApprovedApproved: Chronic hepatitis D virus (HDV) infection in adults with compensated liver diseaseApproved by MHRA following EU conditional approval; reimbursement subject to NICE evaluation.

Granted conditional marketing authorization by EMA in July 2020; converted to full approval in 2024 based on Phase 3 MFR-S312 trial data. Not FDA-approved in the United States as of 2024; investigational use ongoing in the US. Orphan drug designation in EU.

Evidence & Sources

No sources recorded yet.